AU7397094A - Prevention and treatment of alzheimer's disease - Google Patents

Prevention and treatment of alzheimer's disease

Info

Publication number
AU7397094A
AU7397094A AU73970/94A AU7397094A AU7397094A AU 7397094 A AU7397094 A AU 7397094A AU 73970/94 A AU73970/94 A AU 73970/94A AU 7397094 A AU7397094 A AU 7397094A AU 7397094 A AU7397094 A AU 7397094A
Authority
AU
Australia
Prior art keywords
alzheimer
disease
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73970/94A
Inventor
Edward M. Scolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU7397094A publication Critical patent/AU7397094A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
AU73970/94A 1993-08-30 1994-07-05 Prevention and treatment of alzheimer's disease Abandoned AU7397094A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US113880 1987-10-27
US11388093A 1993-08-30 1993-08-30
US11427093A 1993-08-30 1993-08-30
PCT/US1994/007518 WO1995006470A1 (en) 1993-08-30 1994-07-05 Prevention and treatment of alzheimer's disease
US114270 2002-04-02

Publications (1)

Publication Number Publication Date
AU7397094A true AU7397094A (en) 1995-03-22

Family

ID=26811581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73970/94A Abandoned AU7397094A (en) 1993-08-30 1994-07-05 Prevention and treatment of alzheimer's disease

Country Status (2)

Country Link
AU (1) AU7397094A (en)
WO (1) WO1995006470A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964598B2 (en) 1995-10-17 2011-06-21 The J. David Gladstone Institutes ApoE4 domain interaction inhibitors and methods of use thereof
AU7664296A (en) * 1995-11-02 1997-05-22 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
DE19716120A1 (en) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Use of cholesterol-lowering agents
CA2304505A1 (en) 1997-09-24 1999-04-01 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20060141036A1 (en) 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
CA2311356C (en) * 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
EP1584333A3 (en) * 1998-01-28 2009-04-29 Warner-Lambert Company LLC Use of acetylcoenzime A inhibitors for treating Alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
US6472421B1 (en) * 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
US6017913A (en) * 1999-05-03 2000-01-25 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
NZ518822A (en) * 1999-11-04 2004-12-24 Andrx Corp Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
US20020115689A1 (en) * 1999-12-21 2002-08-22 Joanne Waldstreicher Combination therapy for treating neurodegenerative disease
CA2437480A1 (en) * 2001-02-05 2002-08-15 Andrx Corporation Method of treating amyloid .beta. precursor disorder
US20020173535A1 (en) * 2001-02-07 2002-11-21 Renshaw Perry F. Cholesterol-lowering agents as treatment for psychological and cognitive disorders
DE10119680A1 (en) * 2001-04-20 2002-11-14 Boehringer Ingelheim Pharma Use of scavenger compounds to treat and prevent no-dependent microcirculation disorders
US7064130B2 (en) 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
AU2003253056A1 (en) * 2002-07-11 2004-02-02 Austria Wirtschaftsservice Gesellschaft Mit Beschrankter Haftung Use of compounds that activate the sterol regulatory element binding protein (srebp) pathway
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc Method and composition for treating neurodegenerative disorders
WO2005120496A2 (en) * 2004-05-24 2005-12-22 Regents Of The University Of California TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
EP1604686A1 (en) * 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
WO2007074406A2 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
WO2007098417A2 (en) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CN104188940A (en) * 2014-09-26 2014-12-10 天津市聚星康华医药科技有限公司 Simvastatin oral instant film and preparation method thereof

Also Published As

Publication number Publication date
WO1995006470A1 (en) 1995-03-09

Similar Documents

Publication Publication Date Title
AU7397094A (en) Prevention and treatment of alzheimer's disease
IL112050A0 (en) Methods of inhibiting alzheimer's disease
AU4997093A (en) Treatment of alzheimer's disease and modulation of immune system with delta5-androstenes
HU9302551D0 (en) Compounds having effect against hypoglycemia and alzheimer's disease
EP0735870A4 (en) Use of pla 2? inhibitors as treatment for alzheimer's disease
AU674894B2 (en) Treatment of conditions and disease
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
AU3279395A (en) Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
AU4759390A (en) Method of medical treatment of alzheimer's disease
AU1189395A (en) Apolipoprotein e polymorphism and alzheimer's disease
AU4636993A (en) Diagnosing alzheimer's disease and schizophrenia
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
EP0866799A4 (en) Apolipoprotein e2 and treatment of alzheimer's disease
EP0735897A4 (en) "prophylaxis of allergic disease"
AU6678194A (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
AU8185491A (en) Treatment of disease
AU5984196A (en) Treatment and prevention of prostatic disease
AU5293293A (en) Methods and compositions for treatment of allergic disease
AU6955294A (en) Agents for the prevention and treatment of parkinson's disease
GB9516572D0 (en) Prevention and/or treatment of disease
AU1072195A (en) Diagnosis of alzheimer's disease
EP0862442A4 (en) Methods for diagnosis and treatment of bloom's syndrome
AU3053595A (en) Therapeutic treatment and preparations
AU5397994A (en) Treatment of skin disorders
IL111017A0 (en) Transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine and its use for the treatment of alzheimer's disease